Breakthrough: The new anti-aging drugs are synthetic versions of resveratrol which is found in red wine
사람이 150살까지 살 수 있는 약이 개발돼 테스트 중입니다.
영국에서 발행되는 신문 더 메일은 이 약은 레드와인 성분으로 만들었으며 암과 후천적 당뇨를 예방하고 알츠하이머까지도 막을 수 있다고 보도했습니다. 보도에 따르면 아직 피부 검버섯을 막는 데 까진 연구가 진행되지 못했습니다. =
더 메일은 레드 외인 성분인 효소 SIRT 1은 단백질의 활동을 증가시켜 노화를 방지하며 이 약은 앞으로 5년 안에 나올 수 있다고 전했습니다. 여기서의 노화방지란 나이가 들면서 발생하는 질병을 막아주고 수명을 연장한다는 뜻입니다.
하버드 대학 유전학과 데이비드 싱클레어 교수는 이 약은 최종적으로는 암과 알츠하이머, 타잎 2 당뇨(후천성 당뇨)는 물론 심혈관과 심장질환,파킨슨 병과 간경화, 골 다공증, 불면증, 관절염, 대장염, 피부병까지 치료합니다. 또 지금까지의 약이 한가지 질병을 타겟으로 했다면 이 약은 20 가지 질병을 막는 약이라고 설명합니다.
싱클레어 교수의 설명에 따르면 효소 SIRT 1은 칼로리를 제한하고 운동을 하는 효과를 내는데 레드 와인 성분보다 약 100배가 강합니다. 이 약은 제약업계 역사를 새로 쓸 정도라고 말합니다.
더 메일은 이 약을 만드는 기술은 2008년에 GlaxoSmithKline사에 팔렸고 싱클레오 교수에 따르면 첫 타겟은 당뇨가 될 것이며, 다이어트와 운동 효과를 내지만 몸무게는 변하지 않을 것이라고 말합니다. 이미 임상실험을 했습니다.
전문가들은 약이 시판되면 처음에는 처방에 의해 팔리겠으나 점차 예방용으로 복용하게 딜 것으로 예상합니다.
동물실험에서는 이 약을 복용한 뚱뚱한 쥐는 약을 복용하지 않은 날씬한 쥐보다 두배 빨리 뛰었고 15% 오래 살았습니다.
싱클레어 교수는 이 약이 건강한 사람에게도 효능이 있는지를 연구하고 있다면서 인간이 생각하는 것처럼 노화를 거스를 수 없는 것이 아닌 지에 대해서도 연구 중이라고 말합니다. 150살까지 살 수 있는 건 확실한데 추가연구는 필요하다고 밝혔습니다.
—————————-Original Transcript———————–
New drug being developed using compound found in red wine ‘could help humans live until they are 150’
- Drugs are synthetic versions of resveratrol, found in red wine
- Research shows drugs which could prevent cancer and diabetes now viable
- Medication can be taken topically or orally
- No drugs yet developed to target aging skin
PUBLISHED: 15:48 EST, 10 March 2013 | UPDATED: 16:40 EST, 10 March 2013
Breakthrough: The new anti-aging drugs are synthetic versions of resveratrol which is found in red wineDrugs that could combat ageing and help people to live to 150-years-old may be available within five years, following landmark research.
The new drugs are synthetic versions of resveratrol which is found in red wine and is believed to have an anti-ageing effect as it boosts activity of a protein called SIRT1.
Pharmaceutical giant GlaxoSmithKline has been testing the medications on patients suffering with medical conditions including cancer, diabetes and heart disease.
The work proves that a single anti-ageing enzyme in the body can be targeted, with the potential to prevent age-related diseases and extend lifespans.
As each of the 117 drugs tested work on the single enzyme through a common mechanism is means that a whole new class of anti-ageing drugs is now viable, which could ultimately prevent cancer, Alzheimer’s disease and type 2 diabetes.
Genetics professor David Sinclair, based at Harvard University, said: ‘Ultimately, these drugs would treat one disease, but unlike drugs of today, they would prevent 20 others.
‘In effect, they would slow ageing.’
The target enzyme, SIRT1, is switched on naturally by calorie restriction and exercise, but it can also be enhanced through activators.
The most common naturally-occurring activator is resveratrol, which is found in small quantities in red wine, but synthetic activators with much stronger activity are already being developed.
Although research surrounding resveratrol has been going on for a decade, until now the basic science had been contested.
Despite this, there have already been promising results in some trials with implications for cancer, cardiovascular disease and cardiac failure, type 2 diabetes, Alzheimer’s and Parkinson’s diseases, fatty liver disease, cataracts, osteoporosis, muscle wasting, sleep disorders and inflammatory diseases such as psoriasis, arthritis and colitis.
Professor Sinclair said: ‘In the history of pharmaceuticals, there has never been a drug that tweaks an enzyme to make it run faster.’
Positive: Scientists have been testing the medications on patients suffering with medical conditions including cancer, diabetes and heart disease (file picture)The technology was sold to GlaxoSmithKline in 2008.
Four thousand synthetic activators, which are 100 times as potent as a single glass of red wine, have been developed – with the best three being used in human trials.
Writing in the journal Science, Professor Sinclair, who suggests the first therapeutic to be marketed will be for diabetes, said: ‘Our drugs can mimic the benefits of diet and exercise, but there is no impact on weight.’
Limited trials have been carried out in people with type 2 diabetes and the skin inflammatory disease, psoriasis.
Scientists found that there were benefits to the metabolism in the first group and a reduction in skin redness in the second.
The drugs can be administered orally, or topically.
So far, there have been no drugs developed to target ageing skin, but one major skin care range has developed a creme with resveratrol in it.
Anti-aging: Drugs to target ageing skin have not yet been developed, but one major skin care range has created a creme containing resveratrolWhile any drug would be strictly prescribed for certain conditions, Professor Sinclair suggests that one day, they could be taken orally as a preventative.
They could therefore be used in the same way as statin drugs are commonly prescribed to prevent, instead of simply treating, cardiovascular disease.
In animal models, overweight mice given synthetic resveratrol were able to run twice as far as slim mice and they lived 15 per cent longer.
Professor Sinclair added: ‘Now we are looking at whether there are benefits for those who are already healthy.
‘Things there are also looking promising. We’re finding that ageing isn’t the irreversible affliction that we thought it was.
‘Some of us could live to 150, but we won’t get there without more research.’
